Q3 YTD/FY2025 Financial Results

The presentation was conducted in both English and Japanese with simultaneous interpretation.　
Please note that the accuracy of the interpretation cannot be fully guaranteed.

from the beginning

Q3 YTD/FY2025 Financial Results

@Cautionary Statement Regarding Forward-Looking Information

Q3 YTD/FY2025 Overview

I Q3 YTD/FY2025 Consolidated Financial Results FY2025 Revised Forecast

• Q3 YTD/FY2025 Financial Results

• Q3 YTD/FY2025 Financial Results: Main Brands

• Q3 YTD/FY2025 Financial Results: Cost Items

• FY2025 Revised Forecast

II Pipeline Progress

• Strategic Brands: FY2025 Key Expected Events

• zolbetuximab/VYLOY: Latest Status

• Progress in Focus Area Approach

• Progress in ASP3082/setidegrasib & Primary Focus Targeted Protein Degradation

• Key Takeaways

• Upcoming Events

Appendix

• Strategic Brands: Potential Peak Sales (as of Feb 2026)

• Capital Allocation

• Q3 YTD/FY2025 Actual: FX Rate

• FY2025 Forecast: FX Rate & FX Sensitivity

• Balance Sheet & Cash Flow Highlights

• Balance of Bonds and Borrowings Highlights

• Main Intangible Assets (as of Dec 31, 2025)

• Sustainable Margin Transformation

• Robust Pipeline of Astellas

• Progress in Overall PipelinePhase

• Lifecycle Management of Strategic Brands

• enfortumab vedotin (EV) (1/5): Nectin-4 Targeted ADCOverview of Development

• enfortumab vedotin (EV) (2/5): Clinical Studies

• enfortumab vedotin (EV) (3/5): Study Data by Disease Stage of UC

• enfortumab vedotin (EV) (4/5): Study Data in Cis-ineligible MIBC (EV-303)

• enfortumab vedotin (EV) (5/5): Development for Muscle-Invasive Bladder Cancer (MIBC)

• zolbetuximab: Anti-Claudin 18.2 Monoclonal Antibody

• fezolinetant: NK3 Receptor Antagonist

• gilteritinib: FLT3 Inhibitor

• enzalutamide (1/2): Androgen Receptor Inhibitor

• enzalutamide (2/2): Phase 3 Study Data by Disease Stage

• Progress in Focus Area Approach: Current Status of Programs in Clinical Trial

• Overview of Primary Focus Flagship Programs (1/2)

• Overview of Primary Focus Flagship Programs (2/2)

• Pipeline of Primary Focus Targeted Protein Degradation

• Progress in ASP2138 / Primary Focus Immuno-Oncology

• Portfolio of Claudin 18.2-Targeted Therapies

• Progress in ASP7317 (Blindness & Regeneration)

• Progress in AT845 (Genetic Regulation)

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8